BioSpace News Archive

PrinterPrezz Inc., a trailblazer in combining metal 3D printing, nanotechnologies and surgical expertise to design and manufacture next generation medical devices, today announced that Arthur Zafiropoulo, a visionary recognized for his leadership skills and technical expertise throughout the semiconductor industry, will join its board of advisors.

Biologics by McKesson, an independent specialty pharmacy for oncology and other complex therapeutic areas, announced that it has been selected by Karyopharm Therapeutics, Inc. to be in the limited distribution network for XPOVIO™ (selinexor).

Vivacelle Bio, Inc. announces that the US Food and Drug Administration (FDA) has granted Dr. Cuthbert Simpkins, MD its Founder and Chief Innovation Officer, an Investigational New Drug (IND) clearance to proceed with a phase IIa clinical trial of the safety and efficacy of VBI-S.

CEL-SCI Corporation (NYSE American: CVM) announced that one of its key collaborators from Rush University Medical center, Dr. Adrienn Markovitz an Assistant professor in the department of Orthopedic Surgery, presented new LEAPS data at i-Chem2019, International Conference on Immunity and Immunochemistry in San Francisco, California on Wednesday July 3, 2019.

OncoSenX, Inc., a late preclinical-stage company developing therapeutics to kill cancer cells based on their genetics, today announced it has raised $3 million in pre-seed funding to advance its pipeline.

Wize Pharma, Inc. (OTCQB: WIZP) a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, announced today that it has retained Lighthouse BioPartners, LLC

CannTrust has accepted Health Canada’s non-compliance finding and has taken actions to ensure current and future compliance.

Acerus Pharmaceuticals Corporation announced the acceptance of a new manuscript to the Journal of the Endocrine Society, describing how NATESTO® achieves similar symptom improvement, regardless of the degree of a patient’s baseline testosterone deficiency.

The event will be hosted by Sobi’s CEO and President, Guido Oelkers, and the presentation will be held in English.

Skyhawk to expand its collaboration with Biogen to develop novel small molecule RNA splicing modifiers for disease targets